Loading organizations...
§ Private Profile · Irvine, CA, USA
Clinical-stage biotechnology company developing transformative medicines for severe, underserved diseases, focused on CRPS-1.
Ambros Therapeutics is an Irvine, California-based clinical-stage biotechnology company developing transformative medicines for severe and underserved rare diseases. The enterprise is currently advancing neridronate, a non-opioid therapy licensed directly from Abiogen Pharma, targeting Complex Regional Pain Syndrome Type 1. This primary therapeutic asset is progressing through a Phase 3 registrational program scheduled to begin in the first quarter of 2026, having already received Breakthrough Therapy, Fast-Track, and Orphan Drug designations from the Food and Drug Administration. Operating under the leadership of Chief Executive Officer Jay Hagan, the pre-revenue venture relies on institutional capital to fund its clinical trials and regulatory pathways. To support these commercialization efforts, the firm secured $125 million in an oversubscribed Series A financing round backed by RA Capital Management and Enavate Sciences. Ambros Therapeutics was founded in 2025 by Vivek Ramaswamy and Keith Katkin.
Ambros Therapeutics has raised $125.0M across 1 funding round.
Ambros Therapeutics has raised $125.0M in total across 1 funding round.
Ambros Therapeutics has raised $125.0M across 1 funding round. Most recently, it raised $125.0M Series A in December 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Dec 16, 2025 | $125M Series A | Trit Garg, Matthew Hammond | Massimo DI Martino, Adage Capital Management, Arkin BIO Ventures, Balyasny Asset Management, Janus Henderson Investors, Transhuman Capital | Announced |
Ambros Therapeutics has raised $125.0M in total across 1 funding round.
Ambros Therapeutics's investors include Trit Garg, Matthew Hammond, Massimo Di Martino, Adage Capital Management, Arkin Bio Ventures, Balyasny Asset Management, Janus Henderson Investors, Transhuman Capital.